IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Douglass Winthrop Advisors LLC

Douglass Winthrop Advisors LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.2% in the third quarter, Holdings Channel.com reports. The firm owned 438,078 shares of the medical research company’s stock after acquiring an additional 1,076 shares during the quarter. IQVIA makes up about 2.0% of Douglass Winthrop Advisors LLC’s holdings, making the stock its 23rd largest position. Douglass Winthrop Advisors LLC’s holdings in IQVIA were worth $103,811,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA in the second quarter valued at about $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA during the third quarter worth about $27,000. Park Place Capital Corp acquired a new position in IQVIA during the third quarter worth about $28,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Morgan Stanley dropped their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Barclays dropped their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. The Goldman Sachs Group lowered their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Finally, Redburn Atlantic started coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.50.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Up 2.1 %

Shares of IQV stock opened at $201.82 on Monday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $36.63 billion, a PE ratio of 26.49, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51. The business’s fifty day moving average is $222.67 and its 200-day moving average is $227.16. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.